Fractyl Health Inc (GUTS) Stock Price, Quote & News

Company Profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term r...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 902 8800

Website: fractyl.com

Address:

3 Van de Graaff Drive, Suite 200, Burlington, United States

TWITLIEDETECTOR Mar. 16 at 4:38 AM

$GUTS i love it when a stock crashes. that’s why i sit back and watch for signs of life

1 · Reply

LegalTendies Mar. 14 at 10:39 PM

$GUTS finally blocked @Excessive_ , truly a single-minded moron. time spent here should be MUCH more enjoyable with him gone. very

0 · Reply

Excessive_ Mar. 14 at 8:19 PM

$GUTS 1st rs imminent. The chart doesn't lie. They have nothing to stop it. Sometimes you lose. What counts is how fast you overcome the loss and begin to win again. The faster you move on, the less damage you will absorb.

2 · Reply

kellymone2 Mar. 13 at 5:53 PM

@BioRich why don't you show to $SLS 's investors how good your position in $GUTS went since your first call Let me refresh your memory

8 · Reply

Rampage47 Mar. 13 at 5:42 PM

$GUTS bought more

1 · Reply

GeneMachine Mar. 13 at 4:49 PM

$GUTS I'm staying true and following through. https://youtu.be/LAsj8MLPrhk?si=IjMAyL-F2QtXHKI3

0 · Reply

Ked1977 Mar. 13 at 3:43 PM

$GUTS did something happen with this stock? Why is it tanking?

1 · Reply

beanbamba Mar. 13 at 3:36 PM

$GUTS this seems like gone forever. The crook management doesn't provide any info or PR just to keep the shareholders updated. Speaking from ER to ER, no stock can survice. The updates need to be shared on regular basis.

0 · Reply

Tonyboner Mar. 13 at 3:23 PM

$GUTS Big seller here for the laser 4 or 5 days

0 · Reply

Tonyboner Mar. 13 at 3:22 PM

$GUTS Looks ugly, might even head back towards the lows of 38c

0 · Reply

Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance

Feb 2, 2026, 3:04 PM EST - 5 weeks ago

Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts

Jan 30, 2026, 11:46 AM EST - 6 weeks ago

Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS

Jan 29, 2026, 1:48 PM EST - 6 weeks ago

Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product

Jan 29, 2026, 12:32 PM EST - 6 weeks ago

Fractyl Health, Inc. (GUTS) Discusses REMAIN-1 Midpoint Cohort Results on Revita for Weight Maintenance After GLP-1 Discontinuation Transcript

Jan 29, 2026, 7:00 AM EST - 6 weeks ago

Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation

Jan 6, 2026, 7:00 AM EST - 2 months ago

Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness

Jan 5, 2026, 7:00 AM EST - 2 months ago

Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category

Dec 15, 2025, 5:45 PM EST - 3 months ago

Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones

Dec 2, 2025, 7:00 AM EST - 3 months ago

Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Dec 1, 2025, 7:00 AM EST - 3 months ago

Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 8:21 PM EST - 4 months ago

Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:05 PM EST - 4 months ago

Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027

Nov 5, 2025, 7:00 AM EST - 4 months ago

Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025

Oct 7, 2025, 7:00 AM EDT - 5 months ago

Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity

Oct 1, 2025, 5:14 AM EDT - 5 months ago

Fractyl Health: Best-Case Results; Financing Dilutes But Removes Overhang

Sep 26, 2025, 11:07 AM EDT - 6 months ago

Fractyl Health, Inc. - Special Call

Sep 26, 2025, 7:41 AM EDT - 6 months ago

Fractyl Health says experimental procedure helps maintain weight-loss in study

Sep 26, 2025, 7:05 AM EDT - 6 months ago

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock

Sep 26, 2025, 7:00 AM EDT - 6 months ago

Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation

Sep 5, 2025, 6:05 PM EDT - 6 months ago

Fractyl Health: One-Time Procedure To Lock-In GLP-1 Weight Loss; High Risk, High Reward

Sep 3, 2025, 7:00 AM EDT - 6 months ago

Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth

Aug 12, 2025, 8:00 PM EDT - 7 months ago

Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 7 months ago

Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Aug 6, 2025, 4:05 PM EDT - 7 months ago

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

Aug 6, 2025, 8:30 AM EDT - 7 months ago

Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering

Aug 5, 2025, 4:15 PM EDT - 7 months ago

Fractyl Health Announces Proposed Public Offering

Aug 5, 2025, 4:02 PM EDT - 7 months ago

Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure

Jul 16, 2025, 10:13 AM EDT - 8 months ago

Fractyl Health: Speculative Buy With Binary Risk

Jun 23, 2025, 7:40 AM EDT - 9 months ago

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy

Jun 23, 2025, 7:30 AM EDT - 9 months ago

Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models

Jun 18, 2025, 7:00 AM EDT - 9 months ago

Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing

Jun 13, 2025, 7:00 AM EDT - 9 months ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Jun 4, 2025, 7:00 AM EDT - 10 months ago

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide

May 19, 2025, 7:00 AM EDT - 10 months ago

Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

May 17, 2025, 7:15 AM EDT - 10 months ago

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

May 14, 2025, 9:25 AM EDT - 10 months ago

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases

May 13, 2025, 8:43 PM EDT - 10 months ago

Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 10 months ago

Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

May 6, 2025, 7:00 AM EDT - 11 months ago

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

Apr 28, 2025, 4:30 PM EDT - 11 months ago

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

Mar 3, 2025, 8:01 PM EST - 1 year ago

Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:05 PM EST - 1 year ago

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Feb 24, 2025, 7:00 AM EST - 1 year ago

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

Jan 31, 2025, 8:01 AM EST - 1 year ago

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

Dec 12, 2024, 7:00 AM EST - 1 year ago

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Dec 9, 2024, 7:00 AM EST - 1 year ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Nov 26, 2024, 7:00 AM EST - 1 year ago

Fractyl Health to Participate in the Upcoming December Conferences

TWITLIEDETECTOR Mar. 16 at 4:38 AM

$GUTS i love it when a stock crashes. that’s why i sit back and watch for signs of life

1 · Reply

LegalTendies Mar. 14 at 10:39 PM

$GUTS finally blocked @Excessive_ , truly a single-minded moron. time spent here should be MUCH more enjoyable with him gone. very

0 · Reply

Excessive_ Mar. 14 at 8:19 PM

2 · Reply

kellymone2 Mar. 13 at 5:53 PM

@BioRich why don't you show to $SLS 's investors how good your position in $GUTS went since your first call Let me refresh your memory

8 · Reply

Rampage47 Mar. 13 at 5:42 PM

$GUTS bought more

1 · Reply

GeneMachine Mar. 13 at 4:49 PM

$GUTS I'm staying true and following through. https://youtu.be/LAsj8MLPrhk?si=IjMAyL-F2QtXHKI3

0 · Reply

Ked1977 Mar. 13 at 3:43 PM

$GUTS did something happen with this stock? Why is it tanking?

1 · Reply

beanbamba Mar. 13 at 3:36 PM

0 · Reply

Tonyboner Mar. 13 at 3:23 PM

$GUTS Big seller here for the laser 4 or 5 days

0 · Reply

Tonyboner Mar. 13 at 3:22 PM

$GUTS Looks ugly, might even head back towards the lows of 38c

0 · Reply

Nik_CA Mar. 13 at 3:15 AM

$GUTS I’m expecting notice of noncompliance tomorrow or early next week.

2 · Reply

GeneMachine Mar. 12 at 7:31 PM

$GUTS smart hands are heavy here with ~80-90% institutional ownership. The Buy ratings are still firm and that’s the only sentiment that matters to me—no retail is going to shake me out. I’ll be patient with smart money and take the delayed gratification.

0 · Reply

LazyDonut2022 Mar. 12 at 6:29 PM

$SLS Don't forget that this man uses a stock photo of someone looking successful... He cried like a schoolgirl after pumping $GUTS only to see him lose his entire investment. This man is a fraud. And he has a really bad case of Peyronie's.

5 · Reply

SankaYield Mar. 12 at 6:07 PM

$GUTS getting out, wasting my time, putting else where

1 · Reply

Ked1977 Mar. 12 at 4:21 PM

$GUTS the problem with this stock is the criminals running the company lost people so much money than each day they are shorting it to make a little back. There is no confidence in the stock. Unless you are Bioidiot.

1 · Reply

Tonyboner Mar. 12 at 2:59 PM

$GUTS Buy at 45 sell at 48 same day, rinse & repeat !

0 · Reply

tmpl Mar. 10 at 5:52 PM

$GUTS ER is coming soon. What will we get? I expect they can provide more positive updates and progress on the Pivotal Cohort.

0 · Reply

Shodan84 Mar. 10 at 10:10 AM

$GUTS As Warren Buffett said, "Investing is simple, but not easy. The key is patience and discipline."

1 · Reply

mr_grok Mar. 10 at 5:01 AM

$GUTS when will this start making some moves beyond .55 feels like a stretch so far seeing the same old drop of 2-3 cents and pick back up by evening and closing the shop

0 · Reply

Shodan84 Mar. 9 at 7:18 PM

$GUTS 🚀🚀🚀

0 · Reply

GangsterX Mar. 9 at 7:03 PM

$GUTS $CHRS small position here and still holding

1 · Reply

GeneMachine Mar. 9 at 4:09 PM

$GUTS still buying

0 · Reply

Market Cap	63.79M
Revenue (ttm)	90,000.00
Net Income (ttm)	-68.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-76,322.22%
Debt to Equity Ratio	-9.68

Volume	2,459,900
Avg Vol	6,268,692
Day's Range	N/A - N/A
Shares Out	137.04M
Stochastic %K	30%
Beta	1.51
Analysts	Strong Sell
Price Target	$5.24